Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lupuzor extension in SLE
NCT03427151Phase 3Completed
- Sponsor
- ImmuPharma
- Start
- Feb 2018
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of foralumab in systemic lupus erythematosus (SLE), sponsored by ImmuPharma. Started Feb 2018; status: completed.
02
Drugs
foralumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03427151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427151.